Japan’s health ministry approved on Friday the use of rheumatoid arthritis drug Baricitinib for COVID-19 patients, the third such approval following the drugs remdesivir and dexamethasone.
Eli Lilly & Co’s Japan subsidiary had applied to regulators for the new use of the drug in December.
Follow us on:
NIgeria's federal government and organised labour have signed an agreement on the new minimum wage…
A significant escalation in the ongoing conflict between Israel and Hezbollah has occurred following an…
Africa’s largest gathering of creative industry professionals, CANEX WKND, is taking place from October 16-19,…
Sri Lankans are casting their votes in a significant presidential election on Saturday, the first…
Governor Caleb Mutfwang of Plateau State has reaffirmed loyalty to the Peoples Democratic Party (PDP),…
The Nigerian National Petroleum Company Limited (NNPC) has resumed discussions with investors towards bringing back…